Search Results

The role of mitochondrial dysfunction in the cytotoxic synergistic effect of gemcitabine and arsenic on breast cancer.

• Authors : Maleki, Farshid¹ (AUTHOR); Handali, Somayeh² (AUTHOR) ; Rezaei, Mohsen^1,3 (AUTHOR)

Subjects: *ANTINEOPLASTIC combined chemotherapy protocols; *BREAST cancer; *REACTIVE oxygen species

• Source: PLoS ONE. 1/7/2025, Vol. 19 Issue 1, p1-20. 20p.

Record details

Quality of Life in Colon Cancer Patients Managed with FOLFOX Protocol.

• Authors : Mahmood, Hayder Fadhil¹ (AUTHOR) ; Ibrahim, Mazin Judy¹ (AUTHOR)

Subjects: *COLON cancer; *PATIENT compliance; *IRAQIS

• Source: Iraqi Journal of Community Medicine. Jan-Jun2025, Vol. 38 Issue 1, p57-62. 6p.

Record details

Synergistic anticancer activity of Juniperus indica Bertol extract plus 5-fluorouracil against oral squamous cell carcinoma in vitro.

• Authors : Ju-Huei Chien^1,2; Kai-Fu Chang³; Xiao-Fan Huang³

• Source: Tropical Journal of Pharmaceutical Research. Jan2025, Vol. 24 Issue 1, p21-29. 9p.

Record details

Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy.

• Authors : Mishra P; Department of Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India.; Bhurani D

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Cyclophosphamide*/Cyclophosphamide*/Cyclophosphamide*/adverse effects

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Mar; Vol. 66 (3), pp. 516-528. Date of Electronic Publication: 2024 Nov 15.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.

• Authors : Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wierzbowska A

Subjects: Bridged Bicyclo Compounds, Heterocyclic*/Bridged Bicyclo Compounds, Heterocyclic*/Bridged Bicyclo Compounds, Heterocyclic*/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic*/Bridged Bicyclo Compounds, Heterocyclic*/Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic*/Bridged Bicyclo Compounds, Heterocyclic*/Bridged Bicyclo Compounds, Heterocyclic*/adverse effects

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Mar; Vol. 66 (3), pp. 458-468. Date of Electronic Publication: 2024 Nov 28.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.

• Authors : Mims A; Ohio State University, Columbus, OH, USA.; Xie Z

Subjects: Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/mortality ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/diagnosis

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Mar; Vol. 66 (3), pp. 479-487. Date of Electronic Publication: 2024 Nov 28.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma.

• Authors : Wang Y; Hematology Department, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, National Research Center for Translational Medicine (Shanghai), State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai, 200025, China.; Liu YF

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/mortality ; Cyclophosphamide*/Cyclophosphamide*/Cyclophosphamide*/administration & dosage

• Source: Scientific reports [Sci Rep] 2025 Feb 24; Vol. 15 (1), pp. 6538. Date of Electronic Publication: 2025 Feb 24.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China.

• Authors : Long R; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.; Guo H

Subjects: Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/economics ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/therapeutic use

• Source: Scientific reports [Sci Rep] 2025 Feb 21; Vol. 15 (1), pp. 6429. Date of Electronic Publication: 2025 Feb 21.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial.

• Authors : Hong X; Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.; Department of Radiology, Yuebei People's Hospital, Shaoguan, China.

Subjects: Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/pathology ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/mortality

• Source: BMC cancer [BMC Cancer] 2025 Feb 05; Vol. 25 (1), pp. 205. Date of Electronic Publication: 2025 Feb 05.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE).

• Authors : Hirano H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Takahashi N

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Ramucirumab*

• Source: BMC cancer [BMC Cancer] 2025 Feb 04; Vol. 25 (1), pp. 201. Date of Electronic Publication: 2025 Feb 04.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details